27 December 2021>: Human Study
A National Cross-Sectional Study from the Republic of Kosovo on Lot Quality Assurance Sampling (LQAS) to Evaluate the Vaccination Status of Children Between 12 and 24 Months of Age During 2018 to 2020
Bashkim Bejtë Gllareva 1ABCDEFG , Isme Humolli 2ABCDEFG* , Ibrahim Rudhani 3DF , Xhevat Jakupi 4CDF , Jon Rexhepi 5BCDF , Tringa Metaj 6CF , Ardita Kafexholli 7CD , Vlora Sopi 8BDOI: 10.12659/MSMBR.934194
Med Sci Monit Basic Res 2021; 27:e934194
Table 2 Immunization status of children on the day of screening.
Immunization status | N=430 | |
---|---|---|
Not immunized | 3 | 0.7% |
BCG only | 4 | 0.9% |
Partially immunized | 34 | 7.9% |
Complete | 389 | 90.5% |
BCG | ||
In time | 419 | 97.4% |
5 | 1.2% | |
1–3 months late | 1 | 0.2% |
3–6 months late | 2 | 0.5% |
>6 months late | 1 | 0.2% |
Not immunized | 2 | 0.5% |
IPV1 | ||
In time | 351 | 81.6% |
52 | 12.1% | |
1–3 months late | 17 | 4.0% |
3–6 months late | 2 | 0.5% |
>6 months late | 1 | 0.2% |
Not immunized | 7 | 16% |
IPV2 | ||
In time | 346 | 80.5% |
45 | 10.5% | |
1–3 months late | 22 | 5.1% |
3–6 months late | 2 | 0.5% |
>6 months late | 3 | 0.7% |
Not immunized | 12 | 2.8% |
IPV3 | ||
In time | 294 | 68.4% |
67 | 15.6% | |
1–3 months late | 32 | 7.4% |
3–6 months late | 16 | 3.7% |
>6 months late | 6 | 1.4% |
Not immunized | 15 | 3.5% |
MMR | ||
6In time | 181 | 42.1% |
44 | 10.2% | |
1–3 months late | 86 | 20.0% |
3–6 months late | 50 | 11.6% |
>6 months late | 29 | 6.7% |
Not immunized | 40 | 9.3% |
DTP-HepB1 | ||
In time | 351 | 81.6% |
51 | 11.9% | |
1–3 months late | 16 | 3.7% |
3–6 months late | 2 | 0.5% |
>6 months late | 1 | 0.2% |
Not immunized | 9 | 2.1% |
DTP-HepB2 | ||
In time | 346 | 80.5% |
45 | 10.5% | |
1–3 months late | 22 | 5.1% |
3–6 months late | 2 | 0.5% |
>6 months late | 2 | 0.5% |
Not immunized | 13 | 3.0% |
DTP-HepB3 | ||
In time | 294 | 68.4% |
67 | 15.6% | |
1–3 months late | 32 | 7.4% |
3–6 months late | 16 | 3.7% |
>6 months late | 6 | 1.4% |
Not immunized | 15 | 3.5% |
BCG – Bacillus Calmette-Guérin; HBV – hepatitis B virus; DTaP-HB-IPV-Hib – diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b; IPV – inactivated polio vaccine; MMR – measles, mumps, and rubella. |